This Article Abstract Full Text (PDF) All Versions of this Article: 94/8/e72    most recent 01.RES.0000127048.81744.31v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seki, T. Articles by Oh, S. P. Search for Related Content PubMed PubMed Citation Articles by Seki, T. Articles by Oh, S. P. Related Collections Endothelium/vascular type/nitric oxide Mechanism of atherosclerosis/growth factors Other Vascular biology Angiogenesis Animal models of human disease

(Circulation Research. 2004;94:e72.)
© 2004 American Heart Association, Inc.

UltraRapid Communication

Isolation of a Regulatory Region of Activin Receptor-Like Kinase 1 Gene Sufficient for Arterial Endothelium-Specific Expression

Tsugio Seki, Kwon-Ho Hong, Jihye Yun, Seong-Jin Kim, S. Paul Oh

From the Department of Physiology and Functional Genomics (T.S., K.-H.H., J.Y., S.P.O.), University of Florida, College of Medicine, Gainesville, Fla; and the Laboratory of Cell Regulation and Carcinogenesis (S.-J.K.), National Cancer Institute, National Institutes of Health, Bethesda, Md.

Correspondence to S. Paul Oh, Department of Physiology and Functional Genomics, University of Florida, 1600 SW Archer Rd, D5-36, Gainesville, FL 32610. E-mail ohp{at}phys.med.ufl.edu

	Abstract

Top Abstract Introduction Materials and Methods References

 
Activin receptor-like kinase 1 (Acvrl1; Alk1) is a type I receptor for transforming growth factor-ß (TGF-ß). ALK1 plays a pivotal role in vascular development and is involved in the development of hereditary hemorrhagic telangiectasia 2 (HHT2), a dominantly inherited vascular disorder, and pulmonary hypertension. We have previously shown that Alk1 is expressed predominantly in arterial endothelial cells (ECs). Despite recent discoveries of a number of artery-specific genes, the regulatory elements of these genes have not been characterized. To investigate the cis-acting elements essential for the artery-specific Alk1 expression, we have generated a series of transgenic constructs with various lengths and regions of Alk1 genomic fragments connected to a LacZ reporter gene, and analyzed the reporter gene expression in transgenic mice. We found that a 9.2-kb genomic fragment, which includes 2.7-kb promoter region and the entire intron 2, is sufficient to drive arterial endothelium-specific expression. The defined regulatory region, as well as the transgenic mouse lines, would be invaluable resources in studying the mechanisms underlying angiogenesis, arteriogenesis, and vascular disorders, such as HHT and pulmonary hypertension. The full text of this article is available online at http://circres.ahajournals.org.

Key Words: activin receptor-like kinase 1 • artery-specific gene expression • angiogenesis • hereditary hemorrhagic telangiectasia • transforming growth factor-ß

	Introduction

Top Abstract Introduction Materials and Methods References

 
Blood vessels consist of a network of arteries, capillaries, and veins. Recent discoveries of artery- or vein-specific genes, such as ephrinB2 and its receptor EphB4, and some molecules involved in the Notch-delta signaling pathway have contributed to a significant advancement in understanding the mechanisms by which arteries and veins gain their distinct identities during vascular development.¹ In contrast to the long-standing belief that the acquisition of arterial and venous identities is largely determined by different physiological parameters (eg, blood flow, blood pressure, and shear stress), genetic studies in mice and fish suggest that arterial and venous ECs acquire their distinct molecular identities before the establishment of blood flow.^2,3 Studies have shown that the aforementioned artery- or vein-specific genes play crucial roles in angiogenesis and segregation of the two blood vessel types.^2,4,5 It remains unclear, however, whether those genes are directly involved in the morphogenesis of vessel type–specific architecture during development.

ALK1 is a transforming growth factor-ß (TGF-ß) type I receptor in vascular ECs.^6,7 Haploinsufficiency of ALK1 in humans causes HHT2, which is characterized by recurrent epistaxis, localized mucocutaneous telangiectases, and arteriovenous malformations (AVM) in the lungs, liver, and brain.^8,9 Similarly, heterozygous Alk1 mutant mice exhibit HHT-like vascular lesions,¹⁰ whereas Alk1-null homozygotes die at midgestation with hyperdilation of vessels, AVMs, and defects in the differentiation/recruitment of vascular smooth muscle cells (VSMCs).^6,11

Using Alk1-LacZ "knock-in" mice (Alk1^+/LacZ), we have previously observed a dynamic spatiotemporal expression pattern of Alk1: Alk1 is expressed predominantly in arterial ECs throughout the developmental and postnatal growth stages, and its expression is diminished in the adult stage; Alk1 expression is induced in nascent and remodeling arteries during angiogenesis prompted by either wound healing or tumorigenesis.¹² These expression data together with the VSMC defect in Alk1-deficient embryos suggest that ALK1 may be directly involved in the morphogenesis of arterial development and remodeling.

To investigate the cis-acting elements required for the spatiotemporal expression of Alk1 gene (Figure 1a), we have generated three transgenic constructs containing various regions/lengths of putative regulatory sequences connected to the LacZ gene (Figure 1b). The first construct, pXh4.5-SIBN, contained a 2.7-kb promoter, exon 1, and a part of 5' region of intron 2. We established five independent founder lines from this construct, and the transmission of the transgene to F1 offspring was confirmed by genomic Southern blot analyses. The embryos from none of these lines, however, displayed the vascular-specific expression of the LacZ gene. To investigate whether the essential regulatory elements resided in upstream sequences, the 2.7-kb promoter region was extended to a total length of 8 kb in the second construct, pBam9-SIB. Nevertheless, a mouse line from this construct did not exhibit vascular-specific expression pattern of the transgene.

View larger version (29K): [in this window] [in a new window]   Figure 1. Transgenic constructs and the dot plot analysis between human and mouse ALK1 genomic sequences. a, Full mouse Alk1 gene structure. Restriction enzyme sites used for generating the transgenic constructs are indicated by X (XhoI) and B (BamHI). Boxes represent exons, and exon numbers are indicated above. b, Schematic representations of 3 transgenic constructs. Detailed construct information is available in the Materials and Methods. c, Dot plot analysis between partial genomic sequences of human (y-axis) and mouse (x-axis) ALK1 gene. Exon 1 of the human ALK1 gene is split in 2 exons (1 and 2) in the mouse Alk1 gene. Continuous sequence homologies are highlighted by gray shaded areas. Note that the 3' regions of mouse intron-2 and human intron-1 are highly conserved (gray bracket).

These results prompted us to search for the potential regulatory elements by comparing DNA sequences between the human and mouse ALK1 gene loci. Intriguingly, dot plot and blast analyses revealed the presence of highly conserved sequences at the 3' region of intron 2 (Figure 1c). The span of 1.8 kb conserved region in the 3' region of intron 2 consisted of at least five homologous regions ranging from 37 to 145 bp in length, and each sequence cluster showed more than 80% identity (data not shown). Based on this result, we generated the third construct, pXh4.5-in2-SIB, which is similar to the first construct, pXh4.5-SIBN, but with the extension of 3' region to include the remaining intron-2, exon 3, and approximately 300 bp of 5' region of intron 3, for a total length of 9.2 kb (Figure 1b). Two founder lines from this construct showed artery-specific expression of the LacZ gene (Figure 2a), which recapitulated the pattern seen in Alk1^+/LacZ embryos (Figure 2b).

View larger version (82K): [in this window] [in a new window]   Figure 2. Artery-specific LacZ expression in the blood vessels of Tg(Alk1-LacZ) embryos. a and b, Whole-mount X-gal–stained E11.5 Tg(Alk1-LacZ) (a) and Alk1+/LacZ (b) embryos, showing the identical staining pattern but with much higher intensity in Tg(Alk1-LacZ). c and d, Strong LacZ-positive capillary-like vessels in the developing neural tube; the section of E11.5 embryo (c) and a dorsal view of E12.5 neural tube (d). e and f, Sections of X-gal–stained E11.5 Tg(Alk1-LacZ) embryos counterstained with nuclear fast red (NFR) (e) or immunostained with anti-smooth muscle -actin antibodies (f). Note that the X-gal–positive cells were found in a single layer of endothelium in the artery (a, arrowheads), but not in the vein (v), and were not concomitant with VSMCs (f). g and h, Blood vessels on the thoracic wall of newborn pups before (g) and after (h) X-gal staining, showing that only arteries and connecting small arteries were X-gal positive (h). i, Whole-mount X-gal–stained mesenteric vessels of E18.5 fetuses. Only mesenteric artery (a) but not vein (v) showed the transgene expression. j and k, X-gal–stained aorta and intercostal blood vessels before (j) and after (k) clearing with the organic solvents. Similar sizes of intercostal arteries (a) and veins (v) were running side-by-side (j), whereas only arteries and dorsal aorta (ao) were X-gal positive (j and k). X-gal–positive staining in the rib skeleton (*) is from the endogenous ß-gal activity. l, Intense X-gal staining in the lungs and aorta (ao) of E15.5 Tg(Alk1-LacZ) embryos. m, NFR counterstained section of E15.5 lungs showed X-gal–positive arteries (a) and capillaries (arrowheads). Note that bronchial epithelial cells were X-gal negative. Scale bars in c, e, f, and m=50 µm.

To examine detailed regulatory activity of the 9.2-kb Alk1 sequences, we analyzed the LacZ expression in various stages of embryos, adult organs, as well as in wounded skins, and compared the results to those of Alk1^+/LacZ mice. Two transgenic mouse lines from pXh4.5-in2-SIB construct, Tg(Alk1-LacZ)C2 and K1, showed identical expression patterns with slightly different intensity (thus, will be collectively referred as Tg(Alk1-LacZ) hereafter). In embryos, the transgene expression pattern of Tg(Alk1-LacZ) was virtually indistinguishable from Alk1^+/LacZ except for the intensity levels (Figure 2). Strong expressions in the capillaries of perineural tissues in embryonic days 10.5 to 13.5 (E10.5 to E13.5) were consistently observed (Figures 2c and 2d). The transgene expression in Tg(Alk1-LacZ) was detected in developing arterial ECs, but neither in VSMCs nor in venous ECs (Figures 2e and 2f). The artery-specific expression was also clearly shown in internal thoracic arteries (Figures 2g and 2h), mesenteric arteries (Figure 2i), and descending aorta and intercostal arteries (Figures 2j and 2k). Strong expression in the pulmonary vessels (Figures 2l and 2m), and the lack of staining in the liver (data not shown) were also consistent with those in Alk1^+/LacZ.

The X-gal staining patterns of Tg(Alk1-LacZ) mice during postnatal life were also identical in a large extent to the ones of Alk1^+/LacZ mice, in which the intense Alk1 expression in arterial vessels during the postnatal growth phase is greatly diminished in most of the tissues except for the lungs at the adult stage. Consistent with these observations, Tg(Alk1-LacZ) mice showed intense vascular staining, such as in the brain and the iris (Figures 3a and 3b), during the early postnatal growth phase. In the adult stage, however, positive staining was barely detectable in capillary-like small vessels throughout the body except for the moderate expression in the lungs (Figures 3c through 3e). In the skin, the Tg(Alk1-LacZ) mice showed intense staining of arteries at newborn stage (Figure 3f) as observed in Alk1^+/LacZ. Unlike Alk1^+/LacZ mice, however, the expression was faded away in the 2-week-old mice.

View larger version (77K): [in this window] [in a new window]   Figure 3. Postnatal transgene expressions in Tg(Alk1-LacZ) mice. a through d, X-gal–stained blood vessels in the brain (a and c) and the iris (b and d). Intense transgene expression in newborn brain (a) and 2-week-old iris (b) were greatly diminished in the adult stage (c and d). Only speckled staining in small branches (arrowheads) was observed (c and d). e, Adult lung section counterstained with NFR. Alveolar capillaries expressed the transgene in the adult stage. f, Intense staining in the arteries of newborn skin. g through j, X-gal staining in the skin during days 3 (g), 5 (h), 8 (i), and 10 (j) after wounding. LacZ expression was induced during wound healing (arrowheads), but in a limited extent. Number and intensity of X-gal–positive vessels peaked at day 5 after wounding (h) and diminished completely by day 10 (j). Asterisks (*) in g through j indicate the wounds.

We also examined the transgene expression during induced angiogenesis in adult mice using skin wound healing model. Although overall X-gal staining intensity in the skin was lower in Tg(Alk1-LacZ) mice when compared with the Alk1^+/LacZ mice, the expression pattern was comparable. During wound healing in the adult stage, the transgene expression was induced in arterial vessels in a similar fashion as the Alk1^+/LacZ mice, although the staining was significantly lighter and limited in both duration and area (Figures 3g through 3j). Although the vascular staining in the wounded area of the Alk1^+/LacZ mice was present from days 3 to 12 after wounding, staining of the transgenic mice was observed only from days 3 to 8. Also, the staining was restricted to the vessels adjacent to the wounds and did not extend to distant arteries that fed the wound lesion in the transgenic mice.

Our transgenic studies indicate that the conserved intronic regions may contain the enhancer element(s) for the artery-specific Alk1 expression. To investigate whether the 9.2-kb regulatory fragment of Alk1 gene contains common regulatory elements, we have performed DNA sequence homology alignment between the 9.2-kb regulatory sequence and regulatory regions of other known endothelium- or artery-specific genes (for details, see the Materials and Methods section). Extensive homology searches, however, did not show any significant continuous homology region.

To identify potential transcriptional factor binding sites (TFBSs) in the 9.2-kb regulatory fragment, comprehensive in silico analysis with the rVISTA 2.0 program was performed. We found 16 conserved TFBSs for 12 transcriptions factors known to regulate EC-specific genes within the 9.2-kb regulatory fragment (Table; Figure 4). The in vivo relevance of the conserved intronic regions and TFBSs remains to be investigated.

View this table: [in this window] [in a new window]   Table 1. List of Transcription Factors of Which TFBSs Were Found in the Alk1 Regulatory Fragment and Their Respective EC-Specific Target Genes

View larger version (54K): [in this window] [in a new window]   Figure 4. Potential transcriptional factor binding sites identified in the mouse Alk1 pXh4.5-in2 fragment by the rVISTA analysis. Top, 16 TFBS matrixes, which represent TFBSs for 12 different transcription factors. Some transcription factors have multiple TFBS matrixes. For example, SP1 has 4 different TFBS matrixes (SP1, SP1_Q2, SP1_Q4, and SP1_Q6). Positions of each conserved TFBS are indicated as a bar within the matrix. Bottom, Mouse Alk1 gene structure (the top line), and the sequence homology between mAlk1 and hALK1 sequences. Color legends in the boxed area indicate the nature of the highly homologous regions. Repetitive sequences are indicated by green boxes on the bottom line. Only the transcriptional factors known to have active roles in regulating EC-specific genes are shown.

We have demonstrated using transgenic mice that the 9.2-kb fragment of Alk1 gene contains essential regulatory elements for its spatiotemporal expression. We have also presented an intriguing possibility that the conserved region in intron-2 may contain the enhancer elements for the artery-specific gene expression. This study also suggests that the expression pattern observed in the Alk1^+/LacZ mice was not a consequence of Alk1 haploinsufficiency. The variance of expression patterns between Tg(Alk1-LacZ) and Alk1^+/LacZ mice in the skin wounds may be due to either the strain differences, or a lack of additional cis-acting elements involved in the Alk1 expression during wound-induced angiogenesis.

The presented 9.2 kb regulatory fragment, as the first regulatory elements specific for arterial endothelial cells, would provide invaluable information regarding regulatory mechanisms of Alk1, as well as other artery-specific genes. Furthermore, this regulatory fragment can be used to activate or silence a gene in developing arteries to study its function in arteriogenesis and remodeling of arterial vessels.

	Materials and Methods

Top Abstract Introduction Materials and Methods References

 
Transgenic strains were generated at the University of Florida or the National Cancer Institute. All animal procedures performed were reviewed and approved by the University of Florida Institutional Animal Care and Use Committee.

Generation and Characterization of Transgenic Mice
The first two constructs, pXh4.5-SIBN and pBam9-SIB, were generated from XhoI 4.5-kb and BamHI 9.2-kb fragments of Alk1, which contain 2.7 kb and 8 kb of the promoter regions, respectively, as well as exon 1 through a 5' region of intron 2 (Figure 1b). For the third construct, pXh4.5-in2-SIB, the 3' end of the XhoI 4.5 kb fragment was extended to 3' region to include the rest of intron 2, exon 3, and a 5' region of intron 3, for a total length of 9.2 kb. Each Alk1 genomic fragment was connected to either SIBN or SIB cassette, which contained SV40 splicing donor/acceptor signals, internal ribosomal entry sequence, ß-galactosidase cDNA, poly A signal, and with/without a neomycin resistant gene cassette driven by the PGK promoter. The microinjections of the DNA constructs into male pronuclei of fertilized eggs from the FVB strain were performed using established procedures.³⁰ The founder lines were screened by genomic Southern blot using the ß-galactosidase gene as a probe. Several founder lines per construct were further examined for their transgene expression by whole-mount X-gal staining of F1, F2, or F3 embryos at E9.5 or E10.5. Consequently, four pXh4.5-SIBN, one pBam9-SIB, and two pXh4.5-in2-SIB mouse lines were established.

Immunohistochemistry and X-Gal Staining
Mouse embryos and 3-month-old adult tissues were stained with X-gal and photographed before and after clearing as described.¹² For SMC identification, paraffin-embedded whole-mount X-gal–stained samples were stained with anti-smooth muscle -actin (clone: 1A4; Sigma) antibodies using the Vectastain staining kit (Vector Laboratory).

Wound Healing Study
Three full-thickness excisional wounds, 4 mm in diameter each, were created on the back skin of 3-month-old mice and analyzed as previously described.¹²

Sequence Comparison Analyses
Mouse and human ALK1 genomic DNA sequences were obtained from UCSC Genome browser (http://genome.ucsc.edu). To visualize human and mouse ALK1 genomic sequence homology, dot-plot sequence comparison was performed by using the Dot Matcher program available at European Molecular Biology Open Software Suite (http://bioinfo.pbi.nrc.ca:8090/EMBOSS/) (Figure 1c), and DNA sequence homology alignment was conducted using Blast 2 Sequences program (http://www.ncbi.nlm.nih.gov/gorf/bl2.html). The Blast 2 Sequences were also used to search for common regulatory elements between Alk1 and endothelium- or artery-specific genes. The following genes were included: Tek (Tie-2),²⁷ Nos3 (eNOS),³¹ and Cdh5 (VE-cadherin),³² for endothelium-specific genes; and Efnb2 (Ephrin-B2),³³ Bmx,³⁴ Nrp (Neuropilin-1),³⁵ Dll4,³⁶ Notch1,³⁷ Notch3,³⁷ and Notch4,³⁷ for artery-specific genes. Full-length gene sequences as well as 10-kb 5' regulatory regions from each gene were used as queries, and comparisons against 9.2-kb pXh4.5-in2 sequence were performed with default settings.

Analysis of Potential Transcriptional Factor Binding Sites With rVISTA 2.0
To identify potential transcriptional factor binding sites (TFBSs) in the pXh4.5-in2 sequence, the rVISTA 2.0 program³⁸ provided by Lawrence Livermore National Laboratory was utilized (http://rvista.dcode.org/). The program matches TFBS consensus matrix from TRANSFAC 7.3 database (http://www.biobase.de) to query sequences, and test whether matched consensus matrixes are conserved between two query sequences, based on the specific criteria (for details, see Loots et al³⁸). Some transcriptional factors (TFs) have multiple consensus matrixes with different names in the database. Therefore the number of potential TFBS consensus matrixes is usually greater than the number of potential TFs. In addition, the number of TFBSs is also usually greater than the number of TFBS consensus matrixes because each TFBS consensus matrix can be matched to multiple locations in the query sequences. For the Alk1 regulatory element analysis, the same set of sequences used for the dot-plot analysis was inputted to the rVISTA 2.0 program, and potential TFBSs that were conserved between mouse and human sequences were obtained. The program located 471 conserved potential TFBSs in the 9.2-kb mouse sequence, where each TFBS was matched to one of the 112 TFBS consensus matrixes. Among these112 matrixes, 16 TFBS consensus matrixes for the 12 TFs were known to regulate EC-specific genes (Figure 4; Table).

	Acknowledgments

 
This work was supported by the NIH (HL64024) and the American Heart Association (SDG 9930031N) to S.P.O., as well as by an American Heart Association postdoctoral fellowship to T.S.

	Footnotes

 
Original received February 9, 2004; revision received March 22, 2004; accepted March 24, 2004.

	References

Top Abstract Introduction Materials and Methods References

 

1. Lawson ND, Weinstein BM. Arteries and veins: making a difference with zebrafish. Nat Rev Genet. 2002; 3: 674–682.[CrossRef][Medline] [Order article via Infotrieve]
2. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 1998; 93: 741–753.[CrossRef][Medline] [Order article via Infotrieve]
3. Zhong TP, Childs S, Leu JP, Fishman MC. Gridlock signalling pathway fashions the first embryonic artery. Nature. 2001; 414: 216–220.[CrossRef][Medline] [Order article via Infotrieve]
4. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell. 1999; 4: 403–414.[CrossRef][Medline] [Order article via Infotrieve]
5. Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R, Smith GH, Stark KL, Gridley T. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. 2000; 14: 1343–1352.[Abstract/Free Full Text]
6. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E. Activin receptor-like kinase 1 modulates transforming growth factor-ß1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A. 2000; 97: 2626–2631.[Abstract/Free Full Text]
7. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-ß type I receptors. EMBO J. 2002; 21: 1743–1753.[CrossRef][Medline] [Order article via Infotrieve]
8. Abdalla SA, Pece-Barbara N, Vera S, Tapia E, Paez E, Bernabeu C, Letarte M. Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. Hum Mol Genet. 2000; 9: 1227–1237.[Abstract/Free Full Text]
9. van den DS, Mummery CL, Westermann CJ. Hereditary hemorrhagic telangiectasia: an update on transforming growth factor ß signaling in vasculogenesis and angiogenesis. Cardiovasc Res. 2003; 58: 20–31.[Abstract/Free Full Text]
10. Srinivasan S, Hanes MA, Dickens T, Porteous ME, Oh SP, Hale LP, Marchuk DA. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet. 2003; 12: 473–482.[Abstract/Free Full Text]
11. Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet. 2000; 26: 328–331.[CrossRef][Medline] [Order article via Infotrieve]
12. Seki T, Yun J, Oh SP. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res. 2003; 93: 682–689.[Abstract/Free Full Text]
13. Patterson C, Wu Y, Lee ME, DeVault JD, Runge MS, Haber E. Nuclear protein interactions with the human KDR/flk-1 promoter in vivo: regulation of Sp1 binding is associated with cell type-specific expression. J Biol Chem. 1997; 272: 8410–8416.[Abstract/Free Full Text]
14. Gory S, Dalmon J, Prandini MH, Kortulewski T, de Launoit Y, Huber P. Requirement of a GT box (Sp1 site) and two ETS binding sites for vascular endothelial cadherin gene transcription. J Biol Chem. 1998; 273: 6750–6755.[Abstract/Free Full Text]
15. Cowan PJ, Tsang D, Pedic CM, Abbott LR, Shinkel TA, d’Apice AJ, Pearse MJ. The human ICAM-2 promoter is endothelial cell-specific in vitro and in vivo and contains critical Sp1 and GATA binding sites. J Biol Chem. 1998; 273: 11737–11744.[Abstract/Free Full Text]
16. Zhang R, Min W, Sessa WC. Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem. 1995; 270: 15320–15326.[Abstract/Free Full Text]
17. Ronicke V, Risau W, Breier G. Characterization of the endothelium-specific murine vascular endothelial growth factor receptor-2 (Flk-1) promoter. Circ Res. 1996; 79: 277–285.[Abstract/Free Full Text]
18. Wakiya K, Begue A, Stehelin D, Shibuya M. A cAMP response element and an ETS motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene. J Biol Chem. 1996; 271: 30823–30828.[Abstract/Free Full Text]
19. Botella LM, Puig-Kroger A, Almendro N, Sanchez-Elsner T, Munoz E, Corbi A, Bernabeu C. Identification of a functional NF-B site in the platelet endothelial cell adhesion molecule-1 promoter. J Immunol. 2000; 164: 1372–1378.[Abstract/Free Full Text]
20. McLaughlin F, Ludbrook VJ, Kola I, Campbell CJ, Randi AM. Characterisation of the tumour necrosis factor (TNF)- response elements in the human ICAM-2 promoter. J Cell Sci. 1999; 112 (pt 24): 4695–4703.[Abstract]
21. Jahroudi N, Lynch DC. Endothelial-cell-specific regulation of von Willebrand factor gene expression. Mol Cell Biol. 1994; 14: 999–1008.[Abstract/Free Full Text]
22. Kappel A, Schlaeger TM, Flamme I, Orkin SH, Risau W, Breier G. Role of SCL/Tal-1, GATA, and Ets transcription factor binding sites for the regulation of flk-1 expression during murine vascular development. Blood. 2000; 96: 3078–3085.[Abstract/Free Full Text]
23. Gumina RJ, Kirschbaum NE, Piotrowski K, Newman PJ. Characterization of the human platelet/endothelial cell adhesion molecule-1 promoter: identification of a GATA-2 binding element required for optimal transcriptional activity. Blood. 1997; 89: 1260–1269.[Abstract/Free Full Text]
24. Kawana M, Lee ME, Quertermous EE, Quertermous T. Cooperative interaction of GATA-2 and AP1 regulates transcription of the endothelin-1 gene. Mol Cell Biol. 1995; 15: 4225–4231.[Abstract]
25. Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA. Molecular regulation of the endothelin-1 gene by hypoxia: contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol Chem. 2001; 276: 12645–12653.[Abstract/Free Full Text]
26. Lee ME, Temizer DH, Clifford JA, Quertermous T. Cloning of the GATA-binding protein that regulates endothelin-1 gene expression in endothelial cells. J Biol Chem. 1991; 266: 16188–16192.[Abstract/Free Full Text]
27. Schlaeger TM, Bartunkova S, Lawitts JA, Teichmann G, Risau W, Deutsch U, Sato TN. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A. 1997; 94: 3058–3063.[Abstract/Free Full Text]
28. Lelievre E, Mattot V, Huber P, Vandenbunder B, Soncin F. ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin. Oncogene. 2000; 19: 2438–2446.[CrossRef][Medline] [Order article via Infotrieve]
29. Dube A, Thai S, Gaspar J, Rudders S, Libermann TA, Iruela-Arispe L, Oettgen P. Elf-1 is a transcriptional regulator of the Tie2 gene during vascular development. Circ Res. 2001; 88: 237–244.[Abstract/Free Full Text]
30. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR, Roderick TH, Stewart CL, Lilly F, Hansen CT. FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci U S A. 1991; 88: 2065–2069.[Abstract/Free Full Text]
31. van Haperen R, Cheng C, Mees BM, van Deel E, de Waard M, van Damme LC, van Gent T, van Aken T, Krams R, Duncker DJ, de Crom R. Functional expression of endothelial nitric oxide synthase fused to green fluorescent protein in transgenic mice. Am J Pathol. 2003; 163: 1677–1686.[Abstract/Free Full Text]
32. Gory S, Vernet M, Laurent M, Dejana E, Dalmon J, Huber P. The vascular endothelial-cadherin promoter directs endothelial-specific expression in transgenic mice. Blood. 1999; 93: 184–192.[Abstract/Free Full Text]
33. Gale NW, Baluk P, Pan L, Kwan M, Holash J, DeChiara TM, McDonald DM, Yancopoulos GD. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol. 2001; 230: 151–160.[CrossRef][Medline] [Order article via Infotrieve]
34. Ekman N, Lymboussaki A, Vastrik I, Sarvas K, Kaipainen A, Alitalo K. Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. Circulation. 1997; 96: 1729–1732.[Abstract/Free Full Text]
35. Moyon D, Pardanaud L, Yuan L, Breant C, Eichmann A. Plasticity of endothelial cells during arterial-venous differentiation in the avian embryo. Development. 2001; 128: 3359–3370.[Abstract/Free Full Text]
36. Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, Deblandre GA, Kintner CR, Stark KL. Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev. 2000; 14: 1313–1318.[Abstract/Free Full Text]
37. Villa N, Walker L, Lindsell CE, Gasson J, Iruela-Arispe ML, Weinmaster G. Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev. 2001; 108: 161–164.[CrossRef][Medline] [Order article via Infotrieve]
38. Loots GG, Ovcharenko I, Pachter L, Dubchak I, Rubin EM. rVista for comparative sequence-based discovery of functional transcription factor binding sites. Genome Res. 2002; 12: 832–839.[Abstract/Free Full Text]

This article has been cited by other articles:

				S. O. Park, Y. J. Lee, T. Seki, K.-H. Hong, N. Fliess, Z. Jiang, A. Park, X. Wu, V. Kaartinen, B. L. Roman, et al. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2 Blood, January 15, 2008; 111(2): 633 - 642. [Abstract] [Full Text] [PDF]

				R. I. Koleva, B. A. Conley, D. Romero, K. S. Riley, J. A. Marto, A. Lux, and C. P. H. Vary Endoglin Structure and Function: DETERMINANTS OF ENDOGLIN PHOSPHORYLATION BY TRANSFORMING GROWTH FACTOR-beta RECEPTORS J. Biol. Chem., September 1, 2006; 281(35): 25110 - 25123. [Abstract] [Full Text] [PDF]

				C. Varon, F. Tatin, V. Moreau, E. Van Obberghen-Schilling, S. Fernandez-Sauze, E. Reuzeau, I. Kramer, and E. Genot Transforming Growth Factor {beta} Induces Rosettes of Podosomes in Primary Aortic Endothelial Cells. Mol. Cell. Biol., May 1, 2006; 26(9): 3582 - 3594. [Abstract] [Full Text] [PDF]

				T. Stevens Molecular and Cellular Determinants of Lung Endothelial Cell Heterogeneity Chest, December 1, 2005; 128(6_suppl): 558S - 564S. [Abstract] [Full Text] [PDF]

				P. Bertolino, M. Deckers, F. Lebrin, and P. ten Dijke Transforming Growth Factor-{beta} Signal Transduction in Angiogenesis and Vascular Disorders Chest, December 1, 2005; 128(6_suppl): 585S - 590S. [Abstract] [Full Text] [PDF]

				P. Bertolino, M. Deckers, F. Lebrin, and P. ten Dijke Transforming Growth Factor-{beta} Signal Transduction in Angiogenesis and Vascular Disorders Chest, December 1, 2005; 128(6_suppl): 585S - 590S. [Abstract] [Full Text] [PDF]

				F. Lebrin, M. Deckers, P. Bertolino, and P. ten Dijke TGF-{beta} receptor function in the endothelium Cardiovasc Res, February 15, 2005; 65(3): 599 - 608. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 94/8/e72    most recent 01.RES.0000127048.81744.31v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seki, T. Articles by Oh, S. P. Search for Related Content PubMed PubMed Citation Articles by Seki, T. Articles by Oh, S. P. Related Collections Endothelium/vascular type/nitric oxide Mechanism of atherosclerosis/growth factors Other Vascular biology Angiogenesis Animal models of human disease